NCT01953120View on ClinicalTrials.gov

Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

April 30, 2021

Study Completion Date

April 21, 2021

Conditions
Renal Transplant Rejection
Interventions
DRUG

Belatacept

Subjects will receive intravenous belatacept at 5mg/kg every other week starting from day 1 and continuing with weeks 2, 4, 6, and 8, and then monthly at months 3, 4, 5, and 6. At month 6 patients may elect to continue for an additional six-month period of belatacept administration.

Trial Locations (1)

90024

UCLA Kidney Transplant Research, Los Angeles

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of California, Los Angeles

OTHER